Download Free Superantigens Book in PDF and EPUB Free Download. You can read online Superantigens and write the review.

This volume of Current Topics in Microbiology and Immunology is concerned with a class of molecules that are the most potent polyclonal stimulators of T lymphocytes of several species. These molecules have been named "superantigens" because they use a mechanism of T cell stimulation closely mimicking MHC-restricted recognition of specific antigen: they act on variable parts of T cell antigen receptors and are presented by MHC class II molecules. Prototypes of these molecules are the pyrogenic exotoxins produced by S. aureus and S. pyogenes, of which the staphylococcal enterotoxins and the toxic shock syndrome toxin are the best known. Superantigens also occur endogen ously in mice, most notably the enigmatic Mis determinants, that have withstood characterization for nearly 20 years. Only very recently was it found that Mis is probably encoded by endogenous retroviruses. The list of candidates that are implicated as being superantigens is growing. In many cases, however, the proof that a given molecule indeed falls into this category is still missing.
This book provides ample knowledge and better understanding of Streptococcus pyogenes and their superantigens. Many illustrations make this a highly informative book. This book elucidates briefly Streptococcus pyogenes as a strict human pathogen possessing an array of virulence factors. These help in evading host immune responses such as by the activation of non-specific T-cell subpopulations by producing superantigens. This book mainly focuses on streptococcal superantigens and explains how they are different from conventional antigens. Moreover, it elaborates those diseases in which superantigens are actively involved. Useful aspects of superantigens and different therapeutic interventions to eradicate superantigens induced diseased are also discussed.
This up-to-date sourcebook covers viral and bacterial superantigens (SAgs) from molecular structure and immunological processes to pathology and treatment of superantigen-mediated human diseases. Discusses diseases beyond Toxic Shock Syndrome, such as autoimmune and inflammatory skin conditions, as well as the role of superantigens in other infectious diseases. Illustrated with molecular structures of superantigens.
Since the discovery of viral superantigens in 1991, immunologists have made a number of new discoveries. The discoveries, especially those relating to the interplay between the immune system and viruses producing superantigens, have had a great impact on immunology and virology, as it appears that some diseases are triggered or exacerbated by viral superantigens. Viral Superantigens presents a complete review of this new area of study. Edited by a leading researcher and authored by a distinguished team of contributors, this comprehensive analysis covers every aspect of viral superantigens and related subjects, including critical topics such as effects on the T cell repertoire and viral superantigen-mediated diseases. Immunologists and virologists, clinical practitioners, and graduate students will find this book an invaluable resource to encourage further advances in research.
Superantigens constitute a growing family of bacterial and viral proteins that share the capacity of inducing massive activation of the immune system. This volume contains contributions from leaders in the field of classical T cell superantigens and sheds light on relevant B cell superantigens at the molecular and biochemical levels. This is the first volume to put together basic and clinical aspects of the classical T cell superantigens, B cell superantigens and superallergens. It will therefore be indispensable reading to basic and clinical immunologists, microbiologists, virologists and specialists in allergic and immune disorders.
The Janeway's Immunobiology CD-ROM, Immunobiology Interactive, is included with each book, and can be purchased separately. It contains animations and videos with voiceover narration, as well as the figures from the text for presentation purposes.
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.
This book describes the major achievements and discoveries relevant to bacterial protein toxins since the turn of the new century illustrated by the discovery of more than fifty novel toxins (many of them identified through genome screening). The establishment of the three-dimensional crystal structure of more than 20 toxins during the same period offers deeper knowledge of structure-activity relationships and provides a framework to understand how toxins recognize receptors, penetrate membranes and interact with and modify intracellular substrates. - Edited by two of the most highly regarded experts in the field from the Institut Pasteur, France - 14 brand new chapters dedicated to coverage of historical and general aspects of toxinology - Includes the major toxins of both basic and clinical interest are described in depth - Details applied aspects of toxins such as therapy, vaccinology, and toolkits in cell biology - Evolutionary and functional aspects of bacterial toxins evaluated and summarized - Toxin applications in cell biology presented - Therapy (cancer therapy, dystonias) discussed - Vaccines (native and genetically engineered vaccines) featured - Toxins discussed as biological weapons, comprising chapters on anthrax, diphtheria, ricin etc.
This comprehensive ‘Major Reference Book’ compiles all current and latest information on aging skin in a two-volume set. Highly structured with a reader-friendly format, it covers a wide range of areas such as basic sciences, the different diseases and conditions which occur with aging (from malignant to non-malignant), the latest techniques and methods being used such as bioengineering methods and biometrics as well as toxicological and safety considerations for the elderly population. It also illustrates the global consumers’ sociological and psychological implications, ethnicity and gender differences and includes marketing considerations for this elderly group. This unique and comprehensive guide will become the main reference textbook on this topic.
In 1900, for every 1,000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The National Childhood Vaccine Injury Act, passed in 1986, was intended to bolster vaccine research and development through the federal coordination of vaccine initiatives and to provide relief to vaccine manufacturers facing financial burdens. The legislation also intended to address concerns about the safety of vaccines by instituting a compensation program, setting up a passive surveillance system for vaccine adverse events, and by providing information to consumers. A key component of the legislation required the U.S. Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse events, especially in children. Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health events associated with specific vaccines covered by the National Vaccine Injury Compensation Program (VICP), including the varicella zoster vaccine, influenza vaccines, the hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews peer-reviewed primary studies, summarizes their findings, and evaluates the epidemiological, clinical, and biological evidence. It finds that while no vaccine is 100 percent safe, very few adverse events are shown to be caused by vaccines. In addition, the evidence shows that vaccines do not cause several conditions. For example, the MMR vaccine is not associated with autism or childhood diabetes. Also, the DTaP vaccine is not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the VICP, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.